Trial Profile

Clinical Study on the Safety and Efficacy of QN-023a Targeting CD33 in Acute Myeloid Leukemia

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 05 Jan 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs QN-023a (Primary) ; Cyclophosphamide; Cytarabine; Etoposide; Fludarabine
Indications Acute myeloid leukaemia
Focus Adverse reactions

Most Recent Events

29 Dec 2022 Planned End Date changed from 15 Dec 2025 to 24 Dec 2025.
29 Dec 2022 Planned primary completion date changed from 15 Dec 2023 to 24 Dec 2023.
29 Dec 2022 Planned initiation date changed to 24 Dec 2022.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com